Format

Send to

Choose Destination
Eur Urol. 2015 Jan;67(1):7-10. doi: 10.1016/j.eururo.2014.09.005. Epub 2014 Sep 16.

MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets.

Author information

1
YCR Cancer Research Unit, Department of Biology, University of York, York, North Yorkshire, UK.
2
University of Tampere and Tampere University Hospital, BioMediTech, Molecular Biology of Prostate Cancer Group, Tampere, Finland.
3
University of Tampere and Tampere University Hospital, BioMediTech, Molecular Biology of Prostate Cancer Group, Tampere, Finland; Department of Signal Processing, Tampere University of Technology, Tampere, Finland.
4
YCR Cancer Research Unit, Department of Biology, University of York, York, North Yorkshire, UK; Terry Fox Laboratory, Eaves Lab, BC Cancer Research Centre, Vancouver, BC, Canada.
5
Hull York Medical School, University of Hull, Hull, East Yorkshire, UK; Department of Urology, Castle Hill Hospital, Cottingham, East Yorkshire, UK.
6
YCR Cancer Research Unit, Department of Biology, University of York, York, North Yorkshire, UK; Hull York Medical School, University of Hull, Hull, East Yorkshire, UK. Electronic address: n.j.maitland@york.ac.uk.

Abstract

MicroRNA (miRNA) expression profiles were generated from prostate epithelial subpopulations enriched from patient-derived benign prostatic hyperplasia (n=5), Gleason 7 treatment-naive prostate cancer (PCa) (n=5), and castration-resistant PCa (CRPC) (n=3). Microarray expression was validated in an independent patient cohort (n=10). Principal component analysis showed that miRNA expression is clustered by epithelial cell phenotype, regardless of pathologic status. We also discovered concordance between the miRNA expression profiles of unfractionated epithelial cells from CRPCs, human embryonic stem cells (SCs), and prostate epithelial SCs (both benign and malignant). MiR-548c-3p was chosen as a candidate miRNA from this group to explore its usefulness as a CRPC biomarker and/or therapeutic target. Overexpression of miR-548c-3p was confirmed in SCs (fivefold, p<0.05) and in unfractionated CRPCs (1.8-fold, p<0.05). Enforced overexpression of miR-548c-3p in differentiated cells induced stemlike properties (p<0.01) and radioresistance (p<0.01). Reanalyses of published studies further revealed that miR-548c-3p is significantly overexpressed in CRPC (p<0.05) and is associated with poor recurrence-free survival (p<0.05), suggesting that miR-548c-3p is a functional biomarker for PCa aggressiveness. Our results validate the prognostic and therapeutic relevance of miRNAs for PCa management while demonstrating that resolving cell-type and differentiation-specific differences is essential to obtain clinically relevant miRNA expression profiles.

PATIENT SUMMARY:

We report microRNA (miRNA) expression profiles of epithelial cell fractions from the human prostate, including stem cells. miR-548c-3p was revealed as a functional biomarker for prostate cancer progression. The evaluation of miR-548c-3p in a larger patient cohort should yield information on its clinical usefulness.

KEYWORDS:

Biomarker; Castration-resistant prostate cancer; MicroRNA; Stem cells

PMID:
25234358
DOI:
10.1016/j.eururo.2014.09.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center